These findings resonate with prior studies suggesting HPGD’s role as a prognostic biomarker in CRC, where higher levels of this enzyme are associated with improved survival rates of the other cancer types, such as breast cancer [9] and prostate cancer [10]. This evidence concerns the gene HPGD and prostate carcinoma.